Phase I Study of Pazopanib in Combination With Lapatinib or Trastuzumab in Subjects With Solid Tumors.

Trial Profile

Phase I Study of Pazopanib in Combination With Lapatinib or Trastuzumab in Subjects With Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Lapatinib (Primary) ; Pazopanib (Primary) ; Trastuzumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Results of a retrospective analysis of pazopanib from 4 phase I trials in patients with advanced sarcoma (NCT01339871, NCT01430572, NCT01454804, NCT01454804) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 16 Mar 2015 Status changed from active, no longer recruiting to discontinued, as reported by M.D. Anderson Cancer Center.
    • 13 Mar 2015 Status changed from active no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top